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Abstract
Late onset Alzheimer’s disease is the most common form of dementia for which about 30
susceptibility loci have been reported. The aim of the current study is to identify novel
genes associated with Alzheimer’s disease using the largest up-to-date reference single
nucleotide polymorphism (SNP) panel, the most accurate imputation software and a
novel gene-based analysis approach which tests for patterns of association within genes,
in the powerful genome-wide association dataset of the International Genomics of
Alzheimer’s Project Consortium, comprising over 7 million genotypes from 17,008
Alzheimer’s cases and 37,154 controls. In addition to earlier reported genes, we detected
three novel gene-wide significant loci PPARGC1A (p = 2.2× 10−6), RORA
(p = 7.4× 10−7) and ZNF423 (p = 2.1× 10−6). PPARGC1A and RORA are involved in
circadian rhythm; circadian disturbances are one of the earliest symptoms of
Alzheimer’s disease. PPARGC1A is additionally linked to energy metabolism and the
generation of amyloid beta plaques. RORA is involved in a variety of functions apart
from circadian rhythm, such as cholesterol metabolism and inflammation. The ZNF423
gene resides in an Alzheimer’s disease-specific protein network and is likely involved
with centrosomes and DNA damage repair.
Introduction 1
Late Onset Alzheimer’s disease (LOAD) is a devastating neurodegenerative condition 2
with significant genetic heritability [1]. The apolipoprotein E (APOE ) gene is the 3
strongest genetic risk factor for LOAD [2]. Subsequently, more genes were found to be 4
associated with AD development. The Genetic and Environmental Risk in Alzheimer’s 5
Disease (GERAD) Consortium published a Genome-Wide Association Study (GWAS) 6
that identified novel variants in CLU and PICALM which were associated with AD [3]. 7
Concurrently, the European Alzheimer’s Disease Initiative (EADI) identified an 8
association between the CR1 and CLU loci and AD [4]. Subsequent publications by 9
GERAD, the Alzheimer’s Disease Genetic Consortium (ADGC) and Cohorts for Heart 10
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and Aging Research in Genomic Epidemiology (CHARGE) Consortium identified a 11
further 5 novel loci [5] [6] [7]. The International Genomics of Alzheimer’s Project 12
(IGAP) [4] Consortium is an amalgamation of these four different genetic groups 13
(GERAD, EADI, ADGC and CHARGE). Meta-analysis of the 4 GWAS datasets 14
determined 11 novel variants associated with AD. A gene-based analysis has been 15
undertaken in the IGAP AD data using Brown’s method [8]. This approach determined 16
two additional novel genes; TP53INP1 and IGHV1-67 [9]. Additionally, low frequency 17
risk variants have been identified through next generation sequencing (TREM2 ) [10] 18
and a whole-exome association study (PLCG2, TREM2 and ABI3 [11]). 19
Gene-based analysis is an alternative to GWAS analyses, which considers the 20
association of an individual single nucleotide polymorphism (SNP) with disease. 21
Gene-based analyses provide more power due to the aggregate effect of multiple SNPs 22
being larger than that of individual SNPs. For example, determining the association of 23
genes rather than SNPs, is beneficial since genes are more robust across different 24
populations, this is due to the linkage disequilibrium (LD) between SNPs resulting in 25
different SNPs being associated in different populations [12]. Gene-based analyses are 26
being widely used in the field and as expected, are able to identify novel genes or 27
pathways associated with disease. Pathways clustering in eight areas of biology have 28
been found to be associated with AD using the ALIGATOR [13] algorithm [14] [15]. 29
The aim of the current study is to identify novel genes associated with AD using the 30
largest up-to-date reference SNP panel, the most accurate imputation software and a 31
novel gene-based analysis approach. In this study, we used the GERAD data [3] which 32
have been imputed using the latest Haplotype Reference Consortium data (HRC). 33
Polygenic Linkage disequilibrium- Adjusted Risk Score (POLARIS) [16] is a powerful 34
gene-based method which produces a risk score per person per gene, adjusts for LD 35
between SNPs and informs the analysis with summary statistics from an external data 36
set. POLARIS, unlike standard Polygenic Risk Score (PRS) does not require data to be 37
pruned for LD prior to analysis, so it is able to incorporate information from a larger 38
number of SNPs. We employed the POLARIS approach [16] and using the individual 39
genotypes in the GERAD imputed data, produced the risk score for each individual for 40
every gene considered. The IGAP [4] SNP summary statistic data, where the 41
individuals from GERAD were excluded, were used to generate the gene-based PRS. 42
Results 43
For the imputed GERAD data, using a window around the gene of 35kb upstream and 44
10kb downstream [17], SNPs are assigned to 18,087 genes which are plotted on a 45
Manhattan plot in Fig 1. The 12 gene-wide significant genes from this analysis are 46
shown in Table 1, where gene-wide significance is defined as p < 2.5× 10−6 [18]. A large 47
number of genes reside on chromosome 19 and these are likely influenced by the large 48
effect of APOE. Three novel genes have been identified from this analysis: PPARGC1A, 49
RORA and ZNF423. PPARGC1A (peroxisome proliferator-activated receptor gamma 50
co-activator 1alpha) is a master regulator that mainly regulates energy 51
metabolism [19] [20]. It has been linked to the generation of amyloid beta plaques [21] 52
and circadian rhythm [22]. RORA (Retinoic acid receptor-related orphan receptor 53
alpha) is involved in a variety of functions such as circadian rhythm, cholesterol 54
metabolism and inflammation [23]. Its expression is also upregulated in the AD 55
hippocampus [24]. The ZNF423 gene resides in an AD-specific protein network which 56
also includes other AD-related genes such as APOE, CLU, ABCA7, TREM2 etc. [25]. 57
ZNF423 is likely involved with centrosomes and DNA damage repair [26]. The 58
SCARA3 gene overlaps CLU which has previously been identified as being associated 59
with AD [3] [4]. The POLARIS gene-based results for the genes previously identified as 60
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being associated with AD are seen in S1 Table, these genes contain genome-wide 61
significant SNPs (p < 5× 10−8). Table 1 additionally shows the POLARIS gene-based 62
results conditioned on the APOE gene, this is done by including the POLARIS APOE 63
gene risk score into the logistic regression model. ZNF423 conditioned on APOE no 64
longer reaches gene-wide significance, but PPARGC1A and RORA remain significant, 65
suggesting an association independent of APOE. In addition, BCAM, PVRL2 and 66
APOC4-APOC2 on chromosome 19 remain gene-wide significant, even after adjusting 67
for APOE in the model, suggesting a potential signal beyond APOE. To investigate 68
this, we additionally conditioned on BCAM (the most significant chromosome 19 gene 69
after adjusting for APOE ) to determine whether this explains the remaining effect. 70
Results are shown in S2 Table; when conditioning on APOE and BCAM the only 71
remaining gene-wide significant gene on chromosome 19 is APOC4-APOC2, suggesting 72
that the majority of signals on chromosome 19 are explained by APOE and BCAM. We 73
were unable to condition on APOE genotype since these are not available for all 74
subjects, so removal of an association may be due to reduced sample size. 75
Fig 1. Manhattan Plot for the POLARIS Gene-Based Analysis in Imputed
GERAD Data Using a Gene Window 35kb Upstream and 10kb
Downstream.
Table 1. Gene-Wide Significant Genes from POLARIS Gene-based Analysis in GERAD Imputed Data
Using a Gene Window (35kb Upstream and 10kb Downstream)
POLARIS POLARIS, conditioned on APOE
Chr Gene No. of SNPs Beta SE P-value Beta SE P-value
4 PPARGC1A 480 0.877 0.1851 2.2× 10−6 0.920 0.1885 1.0× 10−6
8 SCARA3 (CLU ) 240 0.526 0.1064 7.8× 10−7 0.537 0.1090 8.3× 10−7
15 RORA 1813 0.334 0.0674 7.4× 10−7 0.338 0.0688 9.1× 10−7
16 ZNF423 1056 0.551 0.1163 2.1× 10−6 0.541 0.1187 5.1× 10−6
19 BCL3 88 0.377 0.0674 4.2× 10−9 0.291 0.0656 8.8× 10−6
19 CBLC 50 0.605 0.1161 1.8× 10−7 0.455 0.1183 0.00012
19 BCAM 71 0.556 0.0543 1.4× 10−24 0.492 0.0555 7.6× 10−19
19 PVRL2 160 0.546 0.0299 9.4× 10−75 0.430 0.0491 2.0× 10−18
19 TOMM40 108 0.500 0.0298 3.4× 10−63 0.334 0.0891 0.00018
19 APOE 55 0.520 0.0315 4.4× 10−61 NA NA NA
19 APOC1 34 0.475 0.0315 1.5× 10−51 -0.249 0.1031 0.01575
19 APOC4-APOC2 62 0.615 0.0871 1.6× 10−12 0.419 0.0892 2.5× 10−6
In order to narrow down the disease-associated SNPs for each of these novel genes, 76
we investigated the gene expression patterns using the BRAINEAC [27] database from 77
the UK Brain Expression Consortium. For the PPARGC1A gene the SNP rs67436520, 78
which is downstream of the PPARGC1A gene, has the best cis-expression quantitative 79
trait loci (eQTL) p-value of 3.3× 10−4, this is expressed in the hippocampus. The best 80
cis-eQTL p-value in the RORA gene is 1.5× 10−4, this is for SNP rs113223478 which is 81
78.5kb upstream of the gene, between the NARG2 and ANXA2 genes, and is expressed 82
in the substantia nigra. This SNP will not be included in the POLARIS score, however, 83
it could be tagged by SNPs included in the score. Finally, SNP rs2270396 has the best 84
cis-eQTL p-value in the ZNF423 gene with a p-value of 3.0× 10−5 and is expressed in 85
the frontal cortex. These SNPs were checked in RegulomeDB [28] and Variant Effect 86
Predictor [29]. They are all intergenic variants that are not in any well-defined 87
regulatory region of the genome and do not overlap the best risk SNPs, so it is difficult 88
to predict how these SNPs may affect the regulation of the expression of these genes. 89
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Discussion 90
A gene-based analysis was performed using the individual genotypes in the GERAD 91
imputed data and the summary statistics from IGAP data excluding the GERAD 92
subjects was used to inform the analysis. This analysis expands a gene window around 93
the gene, 35kb upstream and 10kb downstream, which is likely to include 94
transcriptional regulatory elements in the gene [17] and thus contain SNPs influencing 95
gene expression. Three novel genes were found to be associated with AD using the 96
POLARIS method. The novel genes are PPARGC1A, RORA and ZNF423, all of which 97
have credible biological relevance to AD. These results are already adjusted for LD 98
between SNPs in the gene, using the POLARIS methodology. Most of the genes 99
identified before in IGAP data [4] [9] were also identified by POLARIS as statistically 100
significant, however, since previous results are based on IGAP stages 1 and 2, POLARIS 101
p-values were slightly larger. 102
We investigated disease-associated SNPs using expression patterns, which 103
highlighted individual SNPs. A limitation of this analysis is that the POLARIS score 104
tests the aggregated risk across the gene and is unlikely due to a single SNP. 105
The product of the PPARGC1A gene, PGC-1α (Peroxisome proliferator-activated 106
receptor gamma coactivator 1-alpha) is part of the PGC-1 family of transcriptional 107
coactivators that mainly regulate mitochondrial biogenesis to in turn regulate the 108
cellular energy metabolism [19]. It is also involved in other cellular and physiological 109
functions, including the response to a variety of cellular and external stimuli, cellular 110
glucose homeostasis, circadian rhythm, and the regulation of neuronal apoptosis. 111
The regulation of this gene is complex; it has multiple isoforms and alternative 112
promoters [30] and gene expression is regulated by a variety of stimuli, including 113
cytokines, insulin, exercise and the cold [31]. PGC-1α can induce ribosomal 114
transcription under stress conditions such as oxidative stress and exercise [32]. 115
Previous animal model work has shown that overexpression of hPGC-1α in APP23 116
mice improved spatial and recognition memory, along with a significant reduction of Aβ 117
deposition [21]. Furthermore, hPGC-1α overexpression also reduced the levels of 118
proinflammatory cytokines and microglial activation [21] [33]. This suggests a direct 119
link with recent genetic evidence of microglia-mediated innate immune response 120
involvement in AD [11]. In addition, activation of PGC-1α by EKR and p38 inhibitors 121
have been shown to improve spatial and learning memory in Aβ-injected rats [34]. 122
PPARGC1A has also been implicated in the pathogenesis of other neurodegenerative 123
disorders, namely Huntington’s and Parkinson’s diseases [35]. It has been shown that 124
mutated Huntingtin represses PGC-1α, affecting mitochondrial function, hence 125
ribosomal biogenesis may be affected in Huntington’s disease [36]. There is a brain 126
specific promoter 587kb upstream of human PPARGC1A [37], which is located in a 127
genomic region associated with age of onset of Huntington’s disease and relevant here is 128
that hippocampal PGC-1α expression is decreased in the AD brain [38]. A randomised 129
controlled trial of a PPAR-γ agonist, pioglitazone, found improved cognition and 130
regional cerebral blood flow in patients with mild AD [39]. 131
RORA (Retinoic acid receptor-related orphan receptor alpha) is a nuclear hormone 132
receptor with diverse cellular roles [40], for example in immunity, cerebellum 133
development [41], lipid metabolism [42], circadian rhythms and inflammation [23]. 134
RORA regulates its target genes by binding to the ROR response elements (RORE) in 135
the gene regulatory region [43]. It has been shown to regulate more than 3,000 genes in 136
human monocytic and endothelial cell lines [44]. It has a role in the regulation of the 137
BDNF pathway and its expression is upregulated in AD hippocampus [24]. RORA and 138
PPARGC1A are close biological partners, with PGC-1α regulating the expression of a 139
number of clock genes through the coactivation of the ROR family of orphan nuclear 140
receptors [45]. RORA has been shown to be linked to other genes previously implicated 141
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in AD [25] and also has been implicated in a large number of neuropsychiatric disorders, 142
such as post-traumatic stress disorder [46] [47] and autism [48]. Furthermore, RORA 143
trans-activates IL-6 and is thought to be neuro-protective in astrocytes and 144
anti-inflammatory in peripheral tissues [49]. The two genes, RORA and PPARGC1A 145
that we report here provide further evidence of the involvement of inflammation in the 146
pathogenesis of AD. 147
Finally, ZNF423 is a nuclear protein that belongs to the Kruppel-like C2H2 zinc 148
finger proteins. ZNF423 directs bone morphogenetic protein (BMP)-dependent 149
signalling activity and aberrant forms impede B cell differentiation [50]. Furthermore, 150
elevated gene-expression of ZNF423 has been shown to occur in patients with systemic 151
lupus erythematosus, pointing to an impaired function of B cells in human mesenchymal 152
stem cells [51]. ZNF423 resides in an AD-specific protein network [25]. ZNF423 is likely 153
involved with centrosomes and DNA damage repair [26]. It is downregulated in human 154
neuroblastoma and glioma [52] [53] and also has a role in breast cancer [54]. Previously, 155
it also has been shown that missense and LoF variants are likely to be pathogenic for 156
abnormality of brain morphology, Joubert syndrome and Nephronophthisis with 157
autosomal dominant or autosomal recessive inheritance (www.omim.org, 158
https://www.ncbi.nlm.nih.gov/clinvar/). These disorders present with a range of 159
phenotypic characteristics, with the central nervous system being affected too (more 160
specifically the cerebellar vermis). In nur12 mouse model (with introduced nonsense 161
mutation in exon 4 of the mouse Zfp423 gene), Alcaraz et al. [55] observed loss of the 162
corpus callosum, reduction of hippocampus, and a malformation of the cerebellum 163
reminiscent of patients with Dandy-Walker syndrome. Within the cerebellum, Zfp423 164
was observed to be expressed in both ventricular and external germinal zones. Loss of 165
Zfp423 was also observed to lead to diminished proliferation by granule cell precursors 166
in the external germinal layer and abnormal differentiation and migration of ventricular 167
zone-derived neurons and Bergmann glia [55]. 168
Conclusion 169
POLARIS is a gene-based analysis which produces a genetic risk score per individual 170
per gene, whilst adjusting for LD between SNPs in the gene. This methodology was 171
applied to the latest HRC imputation of the GERAD data, and the summary statistics 172
from IGAP (excluding GERAD subjects) were used as weights in the score. This led to 173
the identification of 3 novel genes associated with AD; these genes are PPARGC1A, 174
RORA and ZNF423. There is evidence that these genes are credible candidates in AD, 175
with PPARGC1A and RORA being linked to circadian rhythm, PPARGC1A is 176
implicated in energy metabolism and the generation of amyloid plaques, RORA is linked 177
to cholesterol metabolism and inflammation and ZNF423 is likely involved in DNA 178
damage repair and resides in an AD-specific protein network. 179
Materials and methods 180
The Haplotype Reference Consortium (HRC), version r1.1 2016, was used to impute 181
GERAD genotype data on the Michigan Imputation Server [56], which to date, allows 182
the most accurate imputation of genetic variants. Imputed genotype probabilities (also 183
known as dosages) were converted to the most probable genotype with a probability 184
threshold of 0.9 or greater. SNPs were removed if: their imputation INFO-score< 0.4, 185
minor allele frequency (MAF)< 0.01, missingness of genotypes≥ 0.05 or HWE< 10−6. 186
A total of 6,119,694 variants were retained. To correct for population structure and 187
genotyping differences, all analyses were adjusted for age, gender and the top 3 principal 188
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components. 189
POLARIS was applied to this GERAD (3,332 cases, 9,832 controls; see S3 Table for 190
cohort details) imputed data, using the IGAP [4] data (17,008 cases, 37,154 controls) 191
excluding GERAD subjects (IGAPnoGERAD) as an external dataset to derive weights 192
from the best powered data set avaliable. The IGAP data was imputed using a previous 193
reference panel (1000 genomes, Dec 2010 release). There were 3,169,839 SNPs in 194
common between imputed GERAD and IGAP summary statistics data. The GERAD 195
imputed data contain individual genotypes for every SNP, enabling the production of a 196
risk score per person per gene, and the IGAPnoGERAD data contains effect sizes for 197
every SNP, which are used to weight the risk score. A gene-based risk score was 198
produced for every individual in the GERAD data. 199
POLARIS adjusts for LD between SNPs and therefore, the SNPs were not pruned 200
for LD and the entire data were used in this analysis. POLARIS adjusts for LD by 201
using spectral decomposition of the correlation matrix between SNPs. Such a matrix 202
was derived for each gene using the individual genotypes from the GERAD imputed 203
data. It was ensured that SNPs had consistent reference alleles across both independent 204
datasets; IGAPnoGERAD and imputed GERAD. If alleles in IGAPnoGERAD were 205
coded in the opposite direction to those in GERAD, the summary effect size for the 206
SNP was inverted. SNPs with alleles AT, TA, CG or GC were excluded. 207
SNPs were assigned to genes using GENCODE (v19) gene models [57]. Only genes 208
with known gene status and those marked as protein coding were used. A gene window 209
containing SNPs which were within 35kb upstream and 10kb downstream of the gene 210
was considered. This window was used since it is likely to contain transcriptional 211
regulatory elements [17]. SNPs which belong to multiple genes were assigned to all 212
those genes. In the HRC imputed GERAD data, 2,296,690 SNPs were assigned to 213
18,087 genes. 214
A POLARIS score was produced for each of these genes, and the overall association 215
of the gene with AD is determined using a logistic regression model, adjusting for 216
population covariates, age and sex. 217
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